Bio-Rad Laboratories Inc., which specializes in life science research and clinical diagnostic products, has introduced two PCR detection systems, the CFX Opus 96 Dx System and the CFX Opus 384 Dx System.
These real-time PCR detection systems have been listed with the U.S. Food and Drug Administration for in vitro diagnostic (IVD) testing and meet the CE-IVD requirement for IVD use in Europe. Both systems are also registered with regulatory bodies for IVD use in Singapore and Canada.
The CFX Opus 96 Dx System and the CFX Opus 384 Dx System are the latest additions to Bio-Rad’s portfolio of real-time PCR instruments. The systems are designed to offer accurate, precise quantification to improve assay development and workflow efficiencies and productivity for diagnostic testing and research.
According to the company, the open systems can multiplex up to five targets to provide efficient IVD assay development and testing. The systems are also intended to provide precise quantification and improved thermal cycler performance, while offering easy-to-use desktop management and analysis software with integrated security features.
“We continue to see an increasing demand for real-time PCR systems that offer more efficient workflows and improved data management and analysis that meet regulatory requirements in IVD assay development and testing, and we’re pleased to introduce the CFX Opus Dx Detection Systems to meet these needs,” says Steven Blakely, director for gene expression and software technology at Bio-Rad. “Both systems are robust and secure platforms that leverage Bio-Rad’s long-standing expertise in genomic tools to better serve both research and clinical diagnostic markets.”
For more information, visit Bio-Rad.
Featured Image: The CFX Opus 384 is one of the latest additions to Bio-Rad’s portfolio of real-time PCR instruments. Photo: BIo-Rad Laboratories
